Zimmer Biomet Holdings, Inc., a global medical technology leader, and Paragon 28, Inc., a leading medical device company focused exclusively on the foot and ankle orthopedic segment, recently announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of common stock of Paragon 28 for an upfront payment of $13 per share in cash, corresponding to an equity value of approximately $1.1 billion and an enterprise value of approximately $1.2 billion.